Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
CureVac (CVAC)
NASDAQ:CVAC
CureVac (CVAC) Stock Price & Analysis
1,136 Followers
CVAC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.22 - $10.70
Previous Close$3.29
Volume1.51M
Average Volume (3M)1.27M
Market Cap
$737.97M
Enterprise Value$350.87M
Total Cash (Recent Filing)$402.45M
Total Debt (Recent Filing)$41.82M
Price to Earnings (P/E)―
Beta1.22
Next Earnings
Aug 15, 2024EPS Estimate
-$0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.32
Shares Outstanding223,988,675
10 Day Avg. Volume994,090
30 Day Avg. Volume1,272,967
Standard Deviation0.30
R-Squared0.20
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)1.49
Price to Sales (P/S)13.58
Price to Cash Flow (P/CF)-4.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue11.19
Enterprise Value/Gross Profit-4.97
Enterprise Value/Ebitda-3.91
Forecast
1Y Price Target
$10.25Price Target Upside211.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
CureVac News
PremiumCompany Announcements
CureVac Shareholders Approve Key Resolutions
PremiumCompany Announcements
CureVac Shareholders Approve Board Appointments
PremiumCompany Announcements
CureVac Launches Phase 2 Study for Influenza Vaccine
Bulls Say, Bears Say
Bulls Say
Financial StabilityGSK takes full ownership of COVID-19 and flu mRNA vaccines, providing €400M upfront to CureVac, plus additional potential milestones and royalties.
Partnerships And CollaborationsCureVac announced a multi-target collaboration with MD Anderson for antigen discovery and vaccine development.
Research And DevelopmentThe Phase 1/2 trial for an mRNA vaccine for H5N1 'bird flu' continues to advance with partner GSK, with the candidate having Fast Track designation from the FDA.
Bears Say
Competitive PositioningCompetitive positioning is unclear in a declining commercial market, and Phase 2 flu data disclosure lacked quantitative results, making comparison with competitors challenging.
Financial PerformanceCureVac reported 1Q24 results missing consensus estimates, ending the quarter with cash of €300M due to continued costs related to the first-gen COVID-19 vaccine CVnCoV.
Partnership And CollaborationCVAC’s inability to secure a BioPharma partner for these programs is a disappointment versus investor expectations.
---
Ownership Overview
0.00% Insiders
1.18% Mutual Funds
4.42% Other Institutional Investors
94.40% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CVAC FAQ
What was CureVac’s price range in the past 12 months?
CureVac lowest stock price was $2.21 and its highest was $10.70 in the past 12 months.
What is CureVac’s market cap?
Currently, no data Available
When is CureVac’s upcoming earnings report date?
CureVac’s upcoming earnings report date is Aug 15, 2024 which is in 40 days.
How were CureVac’s earnings last quarter?
Currently, no data Available
Is CureVac overvalued?
According to Wall Street analysts CureVac’s price is currently Undervalued.
Does CureVac pay dividends?
CureVac does not currently pay dividends.
What is CureVac’s EPS estimate?
CureVac’s EPS estimate is -$0.27.
How many shares outstanding does CureVac have?
CureVac has 224,305,680 shares outstanding.
What happened to CureVac’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of CureVac?
Among the largest hedge funds holding CureVac’s share is RA Capital Management. It holds CureVac’s shares valued at 6M.
---
CureVac Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.25 (211.55% Upside)
$10.25 (211.55% Upside)
Blogger Sentiment
Neutral
CVAC Sentiment 50%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 649.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 6.3%
Last 30 Days ▲ 6.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-67.83%
12-Months-Change
Fundamentals
Return on Equity
-47.08%
Trailing 12-Months
Asset Growth
-29.51%
Trailing 12-Months
Company Description
CureVac
CureVac BV a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid that has the potential to improve the lives of people. The company's product portfolio includes clinical and preclinical candidates across multiple disease indications in oncology, prophylactic vaccines and protein therapy. Its clinical programs are CV8102, which it is evaluating in a Phase 1 clinical trial for the treatment of four types of solid tumors, and CV7202, which it is investigating in a Phase 1 clinical trial for potential vaccination against rabies. It is also rapidly advancing its mRNA vaccine program against coronavirus SARS- CoV-2), for which the company initiated a Phase 1 clinical trial.
---
CVAC Company Deck
---
CVAC Earnings Call
Q4 2024
0:00 / 0:00
---
CVAC Stock 12 Month Forecast
Average Price Target
$10.25
▲(211.55% Upside)
Technical Analysis
Best Analysts Covering CVAC
1 Year
1 Year Success Rate
2/22 ratings generated profit
1 Year Average Return
-37.68%
reiterated a buy rating 4 days ago
Copying Roy Buchanan's trades and holding each position for 1 Year would result in 9.09% of your transactions generating a profit, with an average return of -37.68% per trade.
---